Trials / Completed
CompletedNCT00032929
Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1
Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 269 (actual)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Selegiline Transdermal System for the treatment of cocaine dependence.
Detailed description
The study objectives are to assess the efficacy and safety of the Selegiline Transdermal System (STS) in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that selegiline treatment compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selegiline |
Timeline
- Start date
- 2001-03-01
- Primary completion
- 2002-12-01
- First posted
- 2002-04-08
- Last updated
- 2017-01-12
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00032929. Inclusion in this directory is not an endorsement.